Aikido Pharma Inc AIKI:NASDAQ

Last Price$0.48NASDAQ Closing Price as of 4:00PM ET 1/27/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change-0.03(6.05%)
Bid (Size)$0.48 (5)
Ask (Size)$0.48 (18)
Day Low / High$0.47 - 0.51
Volume759.9 K

View Biotechnology IndustryPeer Comparison as of 01/27/2022


Aikido Pharma Inc ( NASDAQ )

Price: $0.48
Change: -0.03 (6.05%)
Volume: 759.9 K
4:00PM ET 1/27/2022

Inuvo Inc ( NYSE MKT LLC )

Price: $0.36
Change: -0.03 (7.94%)
Volume: 776.3 K
4:00PM ET 1/27/2022

NetSol Technologies Inc ( NASDAQ )

Price: $3.87
Change: -0.08 (2.03%)
Volume: 4.2 K
3:59PM ET 1/27/2022

Live Ventures Inc ( NASDAQ )

Price: $26.04
Change: -0.12 (0.47%)
Volume: 3.2 K
3:57PM ET 1/27/2022

Inpixon ( NASDAQ )

Price: $0.41
Change: +0.003 (0.64%)
Volume: 1.0 M
3:59PM ET 1/27/2022

Read more news Recent News

Sector Update: Health Care Stocks Declining This Afternoon
3:53PM ET 1/24/2022 MT Newswires

Health care stocks were sliding this afternoon, with the NYSE Health Care Index falling 2.1% while the SPDR Health Care Select Sector ETF (XLV) was...

Sector Update: Health Care
3:31PM ET 1/24/2022 MT Newswires

Health care stocks continued to sputter this afternoon, with the NYSE Health Care Index falling 2.1% and the SPDR Health Care Select Sector ETF (XLV) down...

AIkido Pharma's Board Authorizes Stock Buyback Program
2:08PM ET 1/24/2022 MT Newswires

The board of AIkido Pharma (AIKI) authorized the company to repurchase up to $3 million of the company's common stock, effective immediately. The shares...

AIkido Pharma Gets Equity Interest in ASP Isotopes
1:48PM ET 12/06/2021 MT Newswires

AIkido Pharma (AIKI) said Monday it has secured a "strategic" equity stake in ASP Isotopes, a supplier of non-nuclear enriched isotopes, for an undisclosed...

View all Commentary and Analysis

No news stories available at this time.

Company Profile

Business DescriptionAIkido Pharma, Inc. is a biotechnology development company, which engages in the provision of diversified portfolio of small-molecule anticancer and antiviral therapeutics in development. Its oncology therapeutics includes treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It also creates broad-spectrum antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19. The company was founded by Gilbert V. Levin and M. Karen Levin in 1967 and is headquartered in New York, NY. View company web site for more details
AddressOne Rockefeller Plaza
New York, New York 10020
Number of Employees6
Recent SEC Filing01/24/20228-K
CEO, Chief Financial Officer & DirectorAnthony C. Hayes

Company Highlights

Price Open$0.51
Previous Close$0.51
52 Week Range$0.42 - 2.55
Market Capitalization$42.9 M
Shares Outstanding89.7 M
SectorHealth Technology
Next Earnings Announcement03/24/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.08
Beta vs. S&P 500N/A
Revenue$28.0 K
Net Profit MarginN/A
Return on Equity-5.92%

Analyst Ratings as of 10/08/2021

Consensus RecommendationConsensus Icon
Powered by Factset